Last reviewed · How we verify

URIDINE TRIACETATE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 5/100

URIDINE TRIACETATE is a drug. It is currently FDA-approved (first approved 2015).

URIDINE TRIACETATE, also known as RG2133, is a small molecule with an unknown mechanism of action. It has been studied in clinical trials for various conditions, including mitochondrial diseases, pancreatic cancer, and hereditary orotic aciduria.

At a glance

Generic nameURIDINE TRIACETATE
ModalitySmall molecule
PhaseFDA-approved
First approval2015

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about URIDINE TRIACETATE

What is URIDINE TRIACETATE?

URIDINE TRIACETATE is a Small molecule drug.

When was URIDINE TRIACETATE approved?

URIDINE TRIACETATE was first approved on 2015.

What development phase is URIDINE TRIACETATE in?

URIDINE TRIACETATE is FDA-approved (marketed).

What are the side effects of URIDINE TRIACETATE?

Common side effects of URIDINE TRIACETATE include Vomiting, Nausea, Diarrhea. Serious adverse events: Grade 3 Nausea and Vomiting.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing